S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Best Buy reports lower 4Q sales and profits as shoppers remain cautious
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
Critical asset just had biggest fall on record (Ad)
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
From Hometown Hero to Franchise Partner — 3 Celebrities Collaborating With Their Hometown Brands
S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Best Buy reports lower 4Q sales and profits as shoppers remain cautious
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
Critical asset just had biggest fall on record (Ad)
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
From Hometown Hero to Franchise Partner — 3 Celebrities Collaborating With Their Hometown Brands
S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Best Buy reports lower 4Q sales and profits as shoppers remain cautious
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
Critical asset just had biggest fall on record (Ad)
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
From Hometown Hero to Franchise Partner — 3 Celebrities Collaborating With Their Hometown Brands
S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Best Buy reports lower 4Q sales and profits as shoppers remain cautious
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
Critical asset just had biggest fall on record (Ad)
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
From Hometown Hero to Franchise Partner — 3 Celebrities Collaborating With Their Hometown Brands
NASDAQ:RXST

RxSight (RXST) Stock Price, News & Analysis

$54.57
-1.82 (-3.23%)
(As of 02/29/2024 ET)
Today's Range
$53.75
$57.80
50-Day Range
$35.51
$57.92
52-Week Range
$13.00
$58.04
Volume
958,718 shs
Average Volume
427,659 shs
Market Capitalization
$1.96 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$49.63

RxSight MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
9.1% Downside
$49.63 Price Target
Short Interest
Healthy
4.34% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.98mentions of RxSight in the last 14 days
Based on 21 Articles This Week
Insider Trading
Selling Shares
$16.08 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.10) to ($0.86) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.56 out of 5 stars

Medical Sector

295th out of 957 stocks

Ophthalmic Goods Industry

3rd out of 7 stocks


RXST stock logo

About RxSight Stock (NASDAQ:RXST)

RxSight, Inc., an ophthalmic medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.

RXST Stock Price History

RXST Stock News Headlines

Stifel Nicolaus Reaffirms Their Buy Rating on RxSight (RXST)
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Oppenheimer Reaffirms Their Buy Rating on RxSight (RXST)
Forecasting The Future: 9 Analyst Projections For RxSight
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Recap: RxSight Q4 Earnings
RxSight (RXST) Set to Announce Quarterly Earnings on Wednesday
RXST Mar 2024 40.000 put
RXST Feb 2024 60.000 call
Stifel Maintains Buy Rating for RxSight: Here's What You Need To Know
The Analyst Landscape: 8 Takes On RxSight
Director Shweta Maniar Sells 6,399 Shares of RxSight Inc
See More Headlines
Receive RXST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for RxSight and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
2/29/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Ophthalmic goods
Sub-Industry
N/A
Current Symbol
NASDAQ:RXST
Fax
N/A
Employees
292
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$49.63
High Stock Price Target
$64.00
Low Stock Price Target
$32.00
Potential Upside/Downside
-9.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-66,760,000.00
Pretax Margin
-71.81%

Debt

Sales & Book Value

Annual Sales
$76.59 million
Book Value
$3.24 per share

Miscellaneous

Free Float
28,314,000
Market Cap
$1.96 billion
Optionable
Optionable
Beta
1.21
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Dr. Ronald M. Kurtz M.D. (Age 61)
    President, CEO & Director
    Comp: $1.03M
  • Ms. Shelley B. Thunen (Age 70)
    CFO & Assistant Secretary
    Comp: $651.36k
  • Dr. Ilya Goldshleger Ph.D. (Age 49)
    Chief Operating Officer
    Comp: $657.81k
  • Mr. Eric J. Weinberg (Age 63)
    Chief Commercial Officer
    Comp: $638.9k
  • Ms. Rebecca Williston
    Vice President of Accounting & Finance
  • Mr. Matt Haller Ph.D.
    Chief Technology Officer
  • Alex Huang
    Investor Relations
  • Mr. Roy Freeman
    Vice President of Marketing
  • Ms. Caroline Vaughn
    Vice President of Human Resources
  • Mr. Scott Gaines
    Senior VP of Commercial Operations & Business Process














RXST Stock Analysis - Frequently Asked Questions

Should I buy or sell RxSight stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for RxSight in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RXST shares.
View RXST analyst ratings
or view top-rated stocks.

What is RxSight's stock price target for 2024?

6 equities research analysts have issued 1-year price objectives for RxSight's stock. Their RXST share price targets range from $32.00 to $64.00. On average, they anticipate the company's stock price to reach $49.63 in the next year. This suggests that the stock has a possible downside of 9.1%.
View analysts price targets for RXST
or view top-rated stocks among Wall Street analysts.

How have RXST shares performed in 2024?

RxSight's stock was trading at $40.32 at the beginning of the year. Since then, RXST shares have increased by 35.3% and is now trading at $54.57.
View the best growth stocks for 2024 here
.

When is RxSight's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our RXST earnings forecast
.

How were RxSight's earnings last quarter?

RxSight, Inc. (NASDAQ:RXST) posted its quarterly earnings results on Wednesday, February, 28th. The company reported ($0.26) EPS for the quarter, beating analysts' consensus estimates of ($0.36) by $0.10. The business earned $28.58 million during the quarter, compared to analysts' expectations of $28.60 million. RxSight had a negative trailing twelve-month return on equity of 31.45% and a negative net margin of 54.57%.

What ETF holds RxSight's stock ?

Invesco Dorsey Wright Healthcare Momentum ETF holds 53,792 shares of RXST stock, representing 1.07% of its portfolio.

What guidance has RxSight issued on next quarter's earnings?

RxSight issued an update on its FY 2024 earnings guidance on Wednesday, February, 28th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $128.0 million-$135.0 million, compared to the consensus revenue estimate of $128.6 million.

When did RxSight IPO?

(RXST) raised $125 million in an initial public offering (IPO) on Friday, July 30th 2021. The company issued 7,350,000 shares at $16.00-$18.00 per share.

Who are RxSight's major shareholders?

RxSight's stock is owned by a number of retail and institutional investors. Top institutional investors include Artisan Partners Limited Partnership (6.67%), Vanguard Group Inc. (4.13%), Nuveen Asset Management LLC (1.94%), Parkman Healthcare Partners LLC (1.43%), No Street GP LP (1.18%) and Northern Trust Corp (0.92%). Insiders that own company stock include Bakker Juliet Tammenoms, Eric Weinberg, Ilya Goldshleger, Jesse Anderson Corley, Robert Keith Warner, Ronald M Md Kurtz, Shelley B Thunen, Shweta Maniar and William J Phd Link.
View institutional ownership trends
.

How do I buy shares of RxSight?

Shares of RXST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RXST) was last updated on 3/1/2024 by MarketBeat.com Staff